ARC Therapeutics Launches to Develop Novel CDK Inhibitors for Advanced and Resistant CancersAgreements, Business, Cancer, CDK 4/6 Inhibitors, CDK2 Inhibitors, Company Launches, Licensing, Oncology, R&D, Small Molecules, TherapeuticsARC Therapeutics launched with a $6 million financing led by founding investor Eshelman Ventures LLC. Read more August 5, 2020/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2020-08-05 16:15:572020-08-05 22:38:30ARC Therapeutics Launches to Develop Novel CDK Inhibitors for Advanced and Resistant Cancers